NCT03964220View on ClinicalTrials.gov

Impact of Tiotropium Add-on Therapy in Patients With Asthma

CompletedOBSERVATIONAL
Enrollment

7,857

Participants

Timeline

Start Date

March 15, 2019

Primary Completion Date

September 20, 2019

Study Completion Date

September 20, 2019

Conditions
Asthma
Interventions
DRUG

Tiotropium Respimat®

Tiotropium Respimat® 1.25 mcg (on top of baseline Inhaled Corticosteroid/Long-acting beta-agonist )

DRUG

Inhaled Corticosteroid/Long-acting beta-agonist

baseline low dose to medium/high dose, baseline medium dose ICS/LABA to high dose ICS/LABA, additional prescription/refill of high-dose-ICS/LABA following the first prescription of baseline high dose ICS/LABA

Trial Locations (1)

10601

eMax Health, White Plains

Sponsors
All Listed Sponsors
lead

Boehringer Ingelheim

INDUSTRY